Gilead Sciences, Inc.
Close on Nov 3, 2026Market cap $207.66BP/E –Yield 1.89%
Gilead Sciences Other HCV (Sovaldi by Year
Other HCV (Sovaldi — legacy breakout) — U.S. sales ($M) ($M)
Gilead Sciences Other HCV (Sovaldi: $104M in FY2023, down 9.6% from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
Source: Form 10-K (filed 2024-02-23) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other HCV (Sovaldi — legacy breakout) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 104 | -9.6% | Form 10-K (filed 2024-02-23) ↗ |
| FY2022 | Dec 31, 2022 | 115 | -3.4% | Form 10-K (filed 2024-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 119 | -9.8% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 132 | -27.5% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 182 | -36.6% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 287 | – | Form 10-K (filed 2021-02-25) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Other HCV (Sovaldi ($M), annual FY2018–FY2023 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-hcv-other-us
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.
See a number that looks wrong?